Phenformin enhances the therapeutic benefit of BRAFⱽ⁶⁰⁰ᴱ inhibition in melanoma
Phenformin enhances the therapeutic benefit of BRAFⱽ⁶⁰⁰ᴱ inhibition in melanoma
About this item
Full title
Author / Creator
Publisher
National Academy of Sciences
Journal title
Language
English
Formats
Publication information
Publisher
National Academy of Sciences
Subjects
More information
Scope and Contents
Contents
Biguanides, such as the diabetes therapeutics metformin and phenformin, have demonstrated antitumor activity both in vitro and in vivo. The energy-sensing AMP-activated protein kinase (AMPK) is known to be a major cellular target of biguanides. Based on our discovery of cross-talk between the AMPK and v-Raf murine sarcoma viral oncogene homolog B1...
Alternative Titles
Full title
Phenformin enhances the therapeutic benefit of BRAFⱽ⁶⁰⁰ᴱ inhibition in melanoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1803126083
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1803126083
Other Identifiers
ISSN
0027-8424
E-ISSN
1091-6490
DOI
10.1073/pnas.1317577110
